AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 142 min read$PDSB

Patrick Soon-Shiong joins PDS Biotechnology (PDSB) board in up to $22M PIPE deal

PDS Biotechnology (PDSB) raised $11.3M in a PIPE deal led by Dr. Patrick Soon-Shiong, who joined the board. The funds will repay debt and advance clinical programs, including PDS0301 for colorectal cancer. Soon-Shiong's NantWorks gained a licensing option for PDS0101.

Original reporting
stocktitan.net
Published Sep 14, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PDSB
Bullish
medium confidence
Mentioned
$PDSB
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PDSBBullishMed
01

Why it matters

The $22M PIPE provides needed capital for advancing PDS0301 into late‑stage trials and adds Dr. Soon‑Shiong's expertise, potentially improving the company's valuation.

02

Market read

Primary corporate financing event for a micro‑cap biotech; may attract short‑term trading interest.

03

What to watch

Execution risk of the Phase 3 trial and reliance on a single high‑profile director.

Relevance 6/10Novelty 7/10Timing: Sep 14, 2026 (today)

Background

PDS Biotechnology (Nasdaq: PDSB) is a clinical‑stage company developing IL‑12 immunocytokine therapies for cancer.

Company-level read

Ticker impact

$PDSBBullishMedium confidence
Context

PDS Biotechnology announced an up to $22.3M PIPE financing and appointed Dr. Patrick Soon-Shiong to its board, providing fresh capital and a high-profile director.

Expected impact

Potential modest upside as investors price in new funding and board credibility.

Evidence & confidence

PIPE financing is a primary corporate action; the amount is material for a micro‑cap biotech and the board addition adds credibility.

Market effects

Sector

May boost sentiment for the oncology immunotherapy sector as a peer secures new funding.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The PIPE dilution could pressure existing shareholders; the raise may signal cash burn concerns.

Key entities

  • Company
    PDS Biotechnology

    Clinical‑stage biotech focused on targeted immunotherapies.

  • Individual
    Patrick Soon‑Shiong

    Renowned biotech entrepreneur and new board member of PDSB.

  • Investor
    Nant Capital

    Lead investor in the PIPE financing.

Read at source← All news

Related articles

OCT 16
$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

finance.yahoo.com2 min
OCT 13
$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

stockstotrade.com6 min
SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min